212 filings
10-Q
2024 Q1
MCRB
Seres Therapeutics Inc
Quarterly report
8 May 24
10:00am
8-K
MCRB
Seres Therapeutics Inc
8 May 24
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
7:05am
8-K
MCRB
Seres Therapeutics Inc
7 May 24
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
5:18pm
8-K
MCRB
Seres Therapeutics Inc
23 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:00am
8-K
MCRB
Seres Therapeutics Inc
8 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:30pm
S-8
1yvv gz75areh
5 Mar 24
Registration of securities for employees
10:13am
8-K
hbnoc5ravp1e9
5 Mar 24
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
7:05am
8-K
m6ns5atid4yv
26 Feb 24
Seres Therapeutics Announces the Appointment of Marella Thorell As Chief Financial Officer and the Retirement of David Arkowitz
7:06am
8-K
6bvumecvqwc7c
30 Jan 24
Other Events
4:01pm
8-K
449kyt06rpdyppei
10 Jan 24
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
7:00am
8-K
9qde296j
9 Jan 24
Regulation FD Disclosure
7:05am
8-K
7fn6a0z7gk 5iwq
2 Jan 24
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
fvd7e
2 Nov 23
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
7:05am
8-K
b4ho8 sbt2a
4 Oct 23
Departure of Directors or Certain Officers
7:00am
EFFECT
8y0s aiv5
16 Aug 23
Notice of effectiveness
12:15am
CORRESP
fn44mnmvf03hutf 0c
11 Aug 23
Correspondence with SEC
12:00am